lobbying_filings_raw: 9a9d9def-b2ed-4952-8fe3-473abbac0430
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | is_amendment | is_no_activity | is_termination | raw_json | registrant_state | registrant_country | registrant_house_id | client_state | client_ppb_state | client_country | client_ppb_country | client_general_description | client_government_entity | affiliated_org_count | client_entity_id | client_government_unit_id | client_match_method | client_match_confidence | income_amount | expense_amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9a9d9def-b2ed-4952-8fe3-473abbac0430 | Q1 | 5073 | DALRYMPLE & ASSOCIATES, LLC | 105000 | BRIGHTON BIOTECH, INC. | 2011 | first_quarter | 2011-04-15T10:21:37.853000-04:00 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/9a9d9def-b2ed-4952-8fe3-473abbac0430/", "filing_uuid": "9a9d9def-b2ed-4952-8fe3-473abbac0430", "filing_type": "Q1", "filing_type_display": "1st Quarter - Report", "filing_year": 2011, "filing_period": "first_quarter", "filing_period_display": "1st Quarter (Jan 1 - Mar 31)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/9a9d9def-b2ed-4952-8fe3-473abbac0430/print/", "filing_document_content_type": "text/html", "income": "10000.00", "expenses": null, "expenses_method": null, "expenses_method_display": null, "posted_by_name": "Donald \"Dack\" Dalrymple, Principal", "dt_posted": "2011-04-15T10:21:37.853000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "1926 N STREET NW", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "WASHINGTON", "registrant_state": "DC", "registrant_zip": "20036", "registrant": {"id": 5073, "url": "https://lda.senate.gov/api/v1/registrants/5073/", "house_registrant_id": 34019, "name": "DALRYMPLE & ASSOCIATES, LLC", "description": "Business Consulting", "address_1": "1926 N Street, NW", "address_2": "Suite 1", "address_3": null, "address_4": null, "city": "Washington", "state": "DC", "state_display": "District of Columbia", "zip": "20036", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "DONALD \"DACK\" DALRYMPLE", "contact_telephone": "+1 202-833-1043", "dt_updated": "2022-04-06T16:04:33.500584-04:00"}, "client": {"id": 105000, "url": "https://lda.senate.gov/api/v1/clients/105000/", "client_id": 125, "name": "BRIGHTON BIOTECH, INC.", "general_description": "Biodefense & Civilian Drug Development", "client_government_entity": false, "client_self_select": false, "state": "MI", "state_display": "Michigan", "country": "US", "country_display": "United States of America", "ppb_state": "MI", "ppb_state_display": "Michigan", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2011-01-10"}, "lobbying_activities": [{"general_issue_code": "DEF", "general_issue_code_display": "Defense", "description": "Small molecule CBRN threat medical countermeasure research and development defense agency funding legislation, appropriations and oversight.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46869, "prefix": "mr", "prefix_display": "MR.", "first_name": "DONALD", "nickname": "DACK", "middle_name": null, "last_name": "DALRYMPLE", "suffix": null, "suffix_display": null}, "covered_position": "Principal", "new": false}], "government_entities": [{"id": 30, "name": "Army, Dept of (Other)"}, {"id": 115, "name": "Ballistic Missile Defense Organization"}, {"id": 134, "name": "Centers For Disease Control & Prevention (CDC)"}, {"id": 25, "name": "Defense, Dept of (DOD)"}, {"id": 236, "name": "Defense Threat Reduction Agency (DTRA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 201, "name": "Homeland Security, Dept of (DHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 139, "name": "Natl Institutes of Health (NIH)"}, {"id": 1, "name": "SENATE"}, {"id": 12, "name": "White House Office"}]}, {"general_issue_code": "HOM", "general_issue_code_display": "Homeland Security", "description": "Small molecule medical countermeasure research and development agency funding, legislation, appropriations, and oversight.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46869, "prefix": "mr", "prefix_display": "MR.", "first_name": "DONALD", "nickname": "DACK", "middle_name": null, "last_name": "DALRYMPLE", "suffix": null, "suffix_display": null}, "covered_position": "Principal", "new": false}], "government_entities": [{"id": 30, "name": "Army, Dept of (Other)"}, {"id": 115, "name": "Ballistic Missile Defense Organization"}, {"id": 134, "name": "Centers For Disease Control & Prevention (CDC)"}, {"id": 25, "name": "Defense, Dept of (DOD)"}, {"id": 236, "name": "Defense Threat Reduction Agency (DTRA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 201, "name": "Homeland Security, Dept of (DHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 139, "name": "Natl Institutes of Health (NIH)"}, {"id": 1, "name": "SENATE"}, {"id": 12, "name": "White House Office"}]}, {"general_issue_code": "MED", "general_issue_code_display": "Medical/Disease Research/Clinical Labs", "description": "Biodefense small molecule medical countermeasure against CBRN threats and orphan drug research and development funding, legislation, appropriations and oversight.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 46869, "prefix": "mr", "prefix_display": "MR.", "first_name": "DONALD", "nickname": "DACK", "middle_name": null, "last_name": "DALRYMPLE", "suffix": null, "suffix_display": null}, "covered_position": "Principal", "new": false}], "government_entities": [{"id": 30, "name": "Army, Dept of (Other)"}, {"id": 115, "name": "Ballistic Missile Defense Organization"}, {"id": 134, "name": "Centers For Disease Control & Prevention (CDC)"}, {"id": 25, "name": "Defense, Dept of (DOD)"}, {"id": 236, "name": "Defense Threat Reduction Agency (DTRA)"}, {"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 34, "name": "Health & Human Services, Dept of (HHS)"}, {"id": 201, "name": "Homeland Security, Dept of (DHS)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 139, "name": "Natl Institutes of Health (NIH)"}, {"id": 1, "name": "SENATE"}, {"id": 12, "name": "White House Office"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} | DC | US | 34019 | MI | MI | US | US | Biodefense & Civilian Drug Development | 0 | 0 | 10000.0 |